Hong Jae Chon

Associate Professor

CHA Bundang Medical Center

South Korea

Research Interests

Explore related searches

Professors in South Korea Professors in Immunology Immunology professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (11)

Seul-Gi Kim

Clinical Associate Professor

CHA Bundang Medical Center

SOUTH KOREA

View details

Han Sang Kim

Associate Professor

Yonsei Cancer Center

SOUTH KOREA

View details

Beom Kyung Kim

Yonsei University College of Medicine

SOUTH KOREA

View details

Chang Woo Kim

Professor

Ajou University School of Medicine

SOUTH KOREA

View details

Sung Hwan Lee

CHA University

SOUTH KOREA

View details

ilhwan kim

Associate Professor

Inje University Ilsan Paik Hospital

SOUTH KOREA

View details

Sanghoon Jung

Assistant Professor

CHA Bundang Medical Center

SOUTH KOREA

View details

Wooram Park

Assistant Professor

Sungkyunkwan University

SOUTH KOREA

View details

Incheon Kang

Assistant Professor

CHA Bundang Medical Center

SOUTH KOREA

View details

Chan Kim

Assistant Professor

CHA University School of Medicine

SOUTH KOREA

View details

Hannah Yang

University of Michigan

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hong Jae Chon

Research Interests

Explore related searches

Contact this professor

Articles (10)

Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.

High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma.

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.

ARID1A Mutation from Targeted NGS Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer

High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma—Reply

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment

Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma

Multifunctional porous microspheres encapsulating oncolytic bacterial spores and their potential for cancer immunotherapy

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma.

Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma

Collaborators (11)

Seul-Gi Kim

Han Sang Kim

Beom Kyung Kim

Chang Woo Kim

Sung Hwan Lee

ilhwan kim

Sanghoon Jung

Wooram Park

Incheon Kang

Chan Kim

Hannah Yang

Make your next move.